Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial

已完结 20 由不可二二发布于 2025/11/16 14:08:42

DOI:10.1016/s0140-6736(25)01720-9
作者：Zheng Wang, Jia Fan, Shaolai Zhou, Yunfan Sun, Fei Liang, Yuan Ji, Fangming Gu, Tao Li, Li Peng, Tao Peng, Xiaolun Huang, Zhenbin Ding, Dousheng Bai, Bangde Xiang, Guang Tan, Tianfu Wen, Yongyi Zeng,
文献类型：期刊论文
补充材料：仅需补充材料

Elsevier

Abstract：BackgroundSurgical resection is the preferred curative approach for patients with early-stage hepatocellular carcinoma, but recurrence remains a major challenge. Consequently, neoadjuvant an

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyPF6? and Na+ Co-Intercalation in Graphite Cathode of Sodium Dual-Ion Batteries by Enhanced Surface Concentration Effect